A new peer-reviewed paper was published today over-viewing the clinical results for the VariLift Interbody Fusion System from Wenzel Spine.
The paper includes results from more than 700 patients, with 96 percent who were treated with VariLift, a standalone, expandable system.
"This retrospective study of such a large patient population further demonstrates the long-term effectiveness of stand-alone interbody fusion using the VariLift System and the ability to obtain excellent clinical outcomes across multiple sites and countries," said Frank Fichtel, MD, a neurosurgeon.
Here are five things to know from the study, published in Medical Devices: Research and Evidence:
1. The clinical summary demonstrates the effectiveness of Wenzel Spine's system using the proprietary expandable IBFD technology.
2. The VariLift System is the only expandable interbody fusion device on the market with FDA clearance for standalone use in cervical and lumbar procedures.
3. The system is commercially available in the United States and Europe.
4. The company is now setting its sights on publishing data from a prospective clinical trial.
5. The technology is designed as an alterative to traditional interbody spinal fusion to reduce the cost of care while maintaining quality.
"As we look toward the future of progressive spinal surgery techniques, we are confident that VariLift will continue to pioneer true MIS fusion that improves long-term clinical outcomes, shortens hospital stays and creates more active and rapid recovery periods," said Wenzel Spine CEO Chad Neely.
More articles on orthopedic devices:
8 new device launches & releases
InVivo Therapeutics secures expanded patent for Neuro-Spinal Scaffold
Medtronic facing product liability lawsuit over Infuse once more